Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia
Alvotech and Lotus Pharmaceutical have signed a licensing and commercialization agreement for two biosimilars, AVT34 and AVT87. This partnership covers the United States and eight Asian markets, allowing Alvotech to retain commercialization rights in the U.S. alongside Lotus, and granting Lotus exclusive rights in Asia. The biosimilars target multiple cancers and hemophilia, aiming to broaden access to high-quality biologics.
Biogen Inc. stock outperforms competitors on strong trading day
On a strong trading day, Biogen Inc. (BIIB) saw its stock advance by 1.13% to $216.78. This performance outpaced the broader market, with the S&P 500 Index rising 0.43% and the Dow Jones Industrial Average rising 0.98%. Biogen Inc. closed just 2.42% below its 52-week high.
How Investors May Respond To Ultragenyx Pharmaceutical (RARE) First FDA Accelerated Approval For GENGLYCOS
Ultragenyx Pharmaceutical's gene therapy, GENGLYCOS, has received FDA accelerated approval for treating glycogen storage disease type Ia (GSDIa) in patients eight years and older. This marks the company's first commercial gene therapy and provides a direct treatment for GSDIa, potentially impacting Ultragenyx's investment narrative. While the approval reduces regulatory risk, investors should monitor the company's high cash burn and short cash runway as key factors affecting future performance.
OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB
OVERSEA CHINESE BANKING Corp Ltd has acquired a new position in Biogen Inc. (NASDAQ:BIIB) stock, purchasing 18,867 shares valued at approximately $4.076 million in the second quarter. This move comes as other institutional investors have also modified their holdings, and analysts have issued a range of ratings from "Strong Buy" to "Sell" with a consensus "Moderate Buy" rating. Biogen recently exceeded earnings estimates, reporting $3.60 EPS against a consensus of $2.94, with revenue up 3.4% year-over-year.
Wealthfront Advisers LLC Acquires Shares of 16,529 Biogen Inc. $BIIB
Wealthfront Advisers LLC recently acquired a new stake of 16,529 shares in Biogen Inc. (NASDAQ:BIIIB) valued at approximately $3.57 million during the second quarter. This move follows similar actions from other major institutional investors, highlighting significant institutional interest in the biotechnology company. Analysts have issued varied ratings for Biogen, with a consensus of "Moderate Buy" and an average target price of $227.07, despite recent stock slides following a trial miss.
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 13,000 Biogen Inc. $BIIB
OVERSEA CHINESE BANKING Corp Ltd has acquired a new position in Biogen Inc. (NASDAQ:BIIB), purchasing 13,000 shares valued at approximately $2.809 million during the second quarter. Other institutional investors also adjusted their holdings in Biogen, which has a "Moderate Buy" consensus rating from analysts and a price target of $227.07. The biotechnology company recently reported stronger-than-expected quarterly earnings and revenue.
66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S
Danske Bank A S recently acquired 66,365 shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, valued at approximately $14.34 million. This purchase is part of broader institutional investment activity, with several other firms also adjusting their holdings in Biogen. The article also details recent analyst ratings, stock performance metrics, and the company's financial results.
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Biogen Inc. (NASDAQ:BIIB) has received a consensus "Moderate Buy" rating from thirty-three brokerages, with an average 12-month price target of $227.07, surpassing its current share price of $214.35. The company recently exceeded quarterly expectations with $3.60 EPS and $2.74 billion in revenue, and institutional investors hold a significant 87.93% of its stock. Several analysts have updated their price targets and ratings, generally maintaining a positive outlook despite some stock slides.
PTC Therapeutics (PTCT) Shares Moved, What Is Behind The Attention Today?
PTC Therapeutics (PTCT) is gaining attention due to an expected completion of the ST-920 approval process in Q4 2026, supported by positive Phase 1/2 data. Despite recent short-term share price dips, its long-term performance remains strong, and analysts view the stock as undervalued, forecasting a fair value of $96.93 against its current $70.52. However, risks include reliance on a few products and ongoing losses that might necessitate further funding.
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus
Biogen (BIIB) is under investor scrutiny due to recent share price movements and its neurology drug portfolio. While a popular narrative suggests the stock is 2.7% undervalued based on long-term Alzheimer's earnings, a P/E analysis shows it trading significantly higher than industry averages, indicating future success is already priced in. Investors are left weighing the optimism around its pipeline against potential valuation risks and the impact of competition.
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus
Biogen (BIIB) is under investor scrutiny due to its neurology drug portfolio and recent share price movements. While a narrative suggests Biogen is 2.7% undervalued based on the long-term potential of its Alzheimer's drug LEQEMBI, another perspective highlights that its P/E ratio of 39.2x is significantly higher than industry averages, indicating the market may already be pricing in considerable future success. Investors are advised to consider both the potential rewards and warning signs before making investment decisions.
Biogen Inc. stock underperforms Thursday when compared to competitors
Biogen Inc. (BIIB) shares fell 3.25% on Thursday, closing at $214.35, underperforming the broader market. This drop occurred on a day when the S&P 500 Index declined by 0.87% and the Dow Jones Industrial Average fell by 1.32%. The stock's decrease ended a two-day winning streak.
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Biogen (BIIB) stock has risen 9% in the last month due to strong Q2 2026 results, beating earnings and sales estimates, and an improved outlook driven by new growth products and strategic M&A. While its legacy MS franchise continues to decline, the company's diversified portfolio, successful integration of acquired assets like Empaveli and Syfovre, and promising late-stage pipeline are offsetting these declines and strengthening investor confidence. Biogen also raised its 2026 revenue and EPS guidance, making it a "Hold" according to Zacks.
Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today?
RedHill Biopharma (NASDAQ:RDHL) is scheduled to report financial results today, placing scrutiny on its commercial execution, development programs, funding, and balance sheet. The article emphasizes that company-specific operational evidence regarding clinical and commercial progress, patient access, and cash discipline is more crucial than broad market assumptions. Readers should focus on qualitative signals like customer decisions, inventory movement, and alignment of capacity with demand to assess the company's real progress.
4,926 Shares in BlackRock $BLK Acquired by Shepherd Financial Partners LLC
Shepherd Financial Partners LLC has acquired 4,926 shares of BlackRock (NYSE:BLK) worth approximately $4.737 million, marking a new position for the firm in the asset manager. Other major institutional investors like Vanguard Group Inc., BlackRock Inc., and State Street Corp also adjusted their holdings in BLK. The article also touches on recent positive and neutral news surrounding BlackRock, including its iShares Bitcoin Trust performance and dividend announcements, alongside some negative sentiment regarding a potential securities investigation.
Meeder Advisory Services Inc. Acquires Shares of 4,608 Biogen Inc. $BIIB
Meeder Advisory Services Inc. recently acquired 4,608 shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, valuing the new position at approximately $996,000. This move is part of broader institutional investor activity, with several other firms also modifying their holdings in Biogen. Analysts currently rate Biogen as a "Moderate Buy" with an average target price of $227.07, despite recent stock slides following a trial miss.
Edmond DE Rothschild Holding S.A. Makes New Investment in Biogen Inc. $BIIB
Edmond DE Rothschild Holding S.A. has acquired a new stake in Biogen Inc. (NASDAQ:BIIB), purchasing 56,064 shares valued at approximately $12.11 million during the second quarter. This investment is part of a trend where various institutional investors have either bought new positions or increased their holdings in the biotechnology company. Analysts currently rate Biogen as a "Moderate Buy" with an average price target of $227.07, and the company recently reported strong quarterly earnings, beating consensus estimates for both EPS and revenue.
BioMarin to acquire Alesta Therapeutics for up to $490 million
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to $215 million. Existing Alesta shareholders will retain interests in a newly formed entity for non-ALE1 assets, and the transaction is expected to close in Q3 2026.
Biogen Inc. stock outperforms competitors on strong trading day
Shares of Biogen Inc. (BIIB) rose 4.24% to $221.56, outperforming the broader market indices like the S&P 500 Index and the Dow Jones Industrial Average. This marks the second consecutive day of gains for the company's stock. The positive performance occurred during a strong trading session for the overall stock market.
Bitdeer Technologies Group (NASDAQ:BTDR) Trading Up 11.5% - What's Next?
Bitdeer Technologies Group (NASDAQ:BTDR) saw its stock price jump by 11.5% to about $10.04 on Wednesday, with significantly increased trading volume. Despite this surge, the company continues to report weak profitability, including negative EPS and net margins, and analysts have a "Moderate Buy" consensus with an average price target of $24.82, although some have recently lowered their targets. Insider activity shows recent share purchases by executives, while institutional investors hold a substantial portion of the company's stock.
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920
PTC Therapeutics' bull case is potentially shifting due to positive renal data and regulatory progress for its gene therapy, ST-920, highlighted by a recent special call. This development underscores PTC's growing focus on rare disease gene therapies and portfolio diversification beyond its current commercial base. While the immediate future still relies on existing product performance, ST-920's advancement offers a new pillar for the company's long-term investment narrative and financial outlook.
Moderna shares double as cancer vaccine data rekindles investor hopes
Moderna's shares more than doubled, adding $30 billion to its market value, after positive late-stage data for its personalized mRNA cancer therapy developed with Merck. This success is critical for Moderna to demonstrate the broader applicability of its mRNA technology beyond COVID-19 vaccines and infectious diseases. The therapy, intismeran, significantly reduced the risk of recurrence and spread of skin cancer when combined with Merck's Keytruda, leading to substantial gains for Moderna and Merck, and causing significant losses for short sellers.
Zai Lab (ZLAB) Posts Positive Phase 3 Results In Autoimmune Myositis
Zai Lab (ZLAB) and argenx announced positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo in autoimmune myositis, marking the first successful late-stage trial for immune-mediated necrotizing myopathy. This progress underscores Zai Lab's immunology efforts and reliance on partnerships, as VYVGART Hytrulo is an externally sourced asset. The results support a broader use case for the drug and strengthen Zai Lab's immunology portfolio as a second pillar alongside oncology.
Mitsubishi UFJ Asset Management Co. Ltd. Takes $77.53 Million Position in Biogen Inc. $BIIB
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a significant new position in Biogen Inc. (NASDAQ:BIIB), purchasing over 358,000 shares valued at approximately $77.53 million during the second quarter. This move makes Mitsubishi UFJ Asset Management Co. Ltd. one of Biogen's institutional investors, who collectively own 87.93% of the company's stock. The article also details other recent institutional investor activities, analyst ratings, and Biogen's financial performance, noting the company's Q2 earnings beat and current stock metrics.
Biogen stock hits 52-week high at 219.94 USD
Biogen (BIIB) stock has reached a new 52-week high of $219.94, driven by positive market sentiment, product pipeline developments, and strategic business decisions. The company reported strong Q2 results, exceeding analyst expectations, and raised its full-year 2026 revenue outlook. Analysts have responded by increasing price targets and reiterating Buy or Outperform ratings, with further growth anticipated from upcoming lupus drug trial results.
Deutsche Bank AG Takes $193.16 Million Position in Biogen Inc. $BIIB
Deutsche Bank AG has acquired a new position in Biogen Inc. (NASDAQ:BIIB), purchasing 894,035 shares valued at approximately $193.16 million during the second quarter. This move makes Deutsche Bank AG a significant institutional holder, owning 0.61% of Biogen's stock. The article also highlights other institutional investors' recent activities in BIIB, Biogen's financial performance, and current analyst ratings, which generally lean towards a "Moderate Buy" despite a recent trial miss.
Diversify Advisory Services LLC Makes New Investment in Howmet Aerospace Inc. $HWM
Diversify Advisory Services LLC has acquired a new stake in Howmet Aerospace Inc. (NYSE:HWM), purchasing 6,867 shares valued at approximately $1.98 million. This investment comes as institutional investors and hedge funds now own 90.46% of the company. Howmet Aerospace recently reported strong financial results, beating EPS estimates and increasing revenue, and has also raised its quarterly dividend.
15,985,736 Shares in Biogen Inc. $BIIB Bought by BlackRock Inc.
BlackRock Inc. has acquired a significant new stake in Biogen Inc. (NASDAQ:BIIB), purchasing over 15.9 million shares valued at approximately $3.45 billion during the second quarter. This investment makes BlackRock Inc. one of the largest institutional holders, owning about 10.82% of Biogen's stock. Other institutional investors also adjusted their positions, and the article provides an overview of Biogen's financial performance, analyst ratings, and company profile.
REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics
RTW Biotech Opportunities Ltd ("RTW Bio") announced that BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company. The deal includes an upfront cash payment of $275 million for Alesta's lead asset, ALE1, which represents a 41% uplift to RTW Bio's carrying value, with potential for an additional $215 million in milestone payments. This marks the sixth acquisition from RTW Bio's portfolio in 2026, validating its strategy of investing in early-stage, differentiated science.
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Stoke Therapeutics (STOK) is gaining attention after its Phase III EMPEROR trial for Dravet syndrome enrolled 162 patients, exceeding its 150-patient target without discontinuations. The stock has seen significant returns over the past year, and analysts currently peg its fair value at $45.10, suggesting it is 28.7% undervalued compared to its current share price of $32.14. However, potential trial underperformance and future pricing decisions for zorevunersen remain key risks.
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD
GSA Capital Partners LLP acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, purchasing 27,525 shares valued at approximately $1.07 million. Institutional investors and hedge funds now own 89.06% of Kodiak Sciences stock. Analyst sentiment for the company is a "Moderate Buy" with an average price target of $48.14, despite missing recent quarterly earnings estimates.
Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Biogen Inc. (BIIB) rose 1.63% on Tuesday to $212.55, breaking a two-day losing streak, despite a generally grim trading session for the broader stock market. The S&P 500 Index fell 0.69% and the Dow Jones Industrial Average declined 0.22%. Despite its daily gains, Biogen Inc. still underperformed compared to its competitors.
(KEYS) Keysight Technologies, Inc. Expects Q4 Revenue Range $1.93B - $1.95B
Keysight Technologies, Inc. has announced its expectations for Q4 revenue, projecting a range between $1.93 billion and $1.95 billion. This follows a strong Q3 performance where the company reported adjusted earnings and revenue increases. The company also anticipates a Q4 adjusted EPS range of $3.34 to $3.40.
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics' Phase III EMPEROR study for zorevunersen in Dravet syndrome has exceeded its enrollment target, with 162 patients enrolled against a goal of 150, and remarkably, zero patient discontinuations. CEO Ian Smith highlighted the drug's tolerability and the trial's strong retention, attributing it partly to the availability of an open-label extension. The study's primary endpoint is seizure reduction, but it also assesses cognitive and behavioral changes, with regulatory submission for a New Drug Application anticipated to begin in Q1 2027.
Pallas Capital Advisors LLC Acquires Shares of 12,859 Biogen Inc. $BIIB
Pallas Capital Advisors LLC has acquired 12,859 shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, valued at approximately $2.78 million. Other institutional investors have also adjusted their positions in Biogen, with 87.93% of the company's stock owned by institutional investors and hedge funds. Analysts have provided mixed but generally positive ratings for Biogen, with an average target price of $227.07, and the company recently reported stronger-than-expected quarterly earnings.
Tortoise Investment Management LLC Invests $3.79 Million in TeraWulf Inc. $WULF
Tortoise Investment Management LLC recently invested $3.79 million in TeraWulf Inc. by acquiring 153,225 shares during the second quarter. This comes as TeraWulf reported weaker-than-expected quarterly earnings, with a significant loss per share and declining revenue, yet analysts maintain a "Moderate Buy" rating with a high average price target. Insider activity also showed a director purchasing shares while the CEO sold shares under a pre-arranged plan.
K.J. Harrison & Partners Inc Makes New $2.16 Million Investment in Biogen Inc. $BIIB
K.J. Harrison & Partners Inc. has made a new investment of approximately $2.16 million in Biogen Inc. by purchasing 10,000 shares. Institutional investors collectively own 87.93% of Biogen, and analysts maintain a "Moderate Buy" rating with an average price target of $227.07. Biogen recently surpassed quarterly expectations, reporting $3.60 EPS and $2.74 billion in revenue, with revenue increasing 3.4% year-over-year.
Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB
Plato Investment Management Ltd recently acquired a new position in Biogen Inc. (NASDAQ:BIIB) during the second quarter, purchasing 6,938 shares valued at approximately $1.49 million. Several other institutional investors have also adjusted their holdings in the biotechnology company. Analysts have issued a "Moderate Buy" consensus rating for Biogen with a target price of $227.07, and the company reported strong Q2 earnings, exceeding analyst estimates.
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Stoke Therapeutics announced that its Phase III EMPEROR study for zorevunersen in Dravet syndrome has surpassed its enrollment target with 162 patients and zero dropouts, attributing the high retention to the drug's tolerability and an open-label extension. The trial's primary endpoint is seizure reduction at week 28, with secondary measures including cognitive and behavioral changes. Stoke plans to begin a rolling New Drug Application submission in Q1 2027, with potential efficacy data for its ADOA treatment expected in H1 2027.
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure
IGC Pharma announced its Q2 2026 financial results, highlighting that its CALMA Alzheimer's trial for IGC-AD1 is nearing enrollment closure, with topline data expected in Q4 2026. Management also elected to convert $1.15 million owed to them into common stock, aligning their interests with shareholders and preserving company cash. Additionally, the company received authorization in Colombia to conduct psilocybin-related development activities for neuropsychiatric symptoms.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for its radiodiagnostic agent, Tauklarify, for identifying tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used for PET imaging of the brain to identify tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. The approval was based on two blinded read studies demonstrating high accuracy and inter-reader agreement.
Lantheus Wins FDA Approval for Alzheimer's Tau PET Imaging Agent
Lantheus Holdings has received FDA approval for Tauklarify, a PET imaging agent designed to detect tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This approval comes as Lantheus prepares for an $8 billion acquisition by Curium and positions Tauklarify in a diagnostic market that has recently seen a rise in blood-based tests and disease-modifying therapies for Alzheimer's. The company plans to support therapeutic programs while determining the path for broader commercial availability.
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk
Satellos Bioscience Inc. (TSX:MSCL) stock dropped 3.39% as investors evaluated its Duchenne muscular dystrophy (DMD) therapy, SAT-3247, against inherent clinical development risks and the competitive biotechnology landscape. The company, focused on muscle-regeneration through muscle stem cells, is a clinical-stage biotech whose valuation hinges on successful human clinical trial results and future commercialization potential. Key risks include development failure, significant financing needs, and intense competition in the DMD market, making it a speculative investment.
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
Lantheus Holdings has received FDA approval for Tauklarify, a radiodiagnostic agent designed to identify tau pathology in adults being evaluated for Alzheimer's disease. Tauklarify is used in PET imaging of the brain to detect tau neurofibrillary tangle (NFT) pathology, a key biomarker for Alzheimer's. This approval is based on two blinded read studies that demonstrated high accuracy and strong inter-reader agreement.
Biogen stock holds steady as new Alzheimer’s imaging agent reshapes dementia diagnostics
Biogen's stock is stable at $209.83 following a strong Q2 2026 earnings beat, with EPS of $3.60 and revenue of $2.74 billion, surpassing analyst expectations. The company's valuation remains modest, with a P/E ratio of 8.74, and analysts project a moderate upside of 8.22%. A new FDA-approved tau PET imaging agent, TAUKLARIFY, is expected to enhance Alzheimer’s diagnostics and potentially refine Biogen’s clinical trial strategies and treatment pathways for dementia.
Nippon Life Global Investors Americas Inc. Buys New Stake in Biogen Inc. $BIIB
Nippon Life Global Investors Americas Inc. has acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, purchasing 137,220 shares valued at approximately $29.65 million. This investment makes Biogen the 27th largest position in Nippon Life Global Investors Americas Inc.'s portfolio, representing 1.2% of its total holdings. Other institutional investors also made significant changes to their Biogen holdings, while analysts maintain a "Moderate Buy" consensus rating for the stock.
Crown Advisors Management Inc. Makes New $3.06 Million Investment in Build-A-Bear Workshop, Inc. $BBW
Crown Advisors Management Inc. has initiated a new $3.06 million investment in Build-A-Bear Workshop, acquiring 100,000 shares, which now constitutes 1.7% of its portfolio. This comes as institutional ownership in Build-A-Bear remains high at 79.3%, with several firms increasing their stakes. The specialty retailer recently beat earnings estimates and declared a quarterly dividend, maintaining a "Moderate Buy" consensus among analysts.
Bellecapital International Ltd. Acquires 8,728 Shares of AbbVie Inc. $ABBV
Bellecapital International Ltd. increased its stake in AbbVie Inc. by 13% during the second quarter, acquiring an additional 8,728 shares, bringing its total holdings to 75,615 shares valued at approximately $19.0 million. Institutional investors and hedge funds now collectively own 70.23% of AbbVie. The company continues to receive positive analyst sentiment and has a "Moderate Buy" rating with an average target price of $275.50, driven by strong earnings, neuroscience growth, and post-Humira diversification strategies.
AbbVie Inc. $ABBV Shares Bought by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC significantly increased its stake in AbbVie Inc. by 204.3% in Q2, bringing its total holdings to 105,544 shares valued at $26.6 million. This comes as AbbVie reported strong Q1 2026 earnings, with revenue up 12.4% year-over-year and EPS exceeding expectations, driven by growth in its neuroscience, immunology, and aesthetics portfolios. Analysts maintain a "Moderate Buy" rating for ABBV with an average price target of $275.50, despite some concerns about valuation and pipeline uncertainty.
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma announced its Q2 2026 financial results and provided an update on its lead Alzheimer's program, IGC-AD1. The company's Phase 2 CALMA trial for agitation associated with Alzheimer's dementia is nearing enrollment closure, with topline data expected in Q4 2026. Management elected to convert $1.15 million of owed amounts into common stock, strengthening alignment with shareholders and preserving cash.
